CY1122729T1 - Συμπλοκο παραγοντα viii με χτεν και πρωτεϊνη παραγοντα von willebrand, και χρησεις αυτου - Google Patents
Συμπλοκο παραγοντα viii με χτεν και πρωτεϊνη παραγοντα von willebrand, και χρησεις αυτουInfo
- Publication number
- CY1122729T1 CY1122729T1 CY20201100105T CY201100105T CY1122729T1 CY 1122729 T1 CY1122729 T1 CY 1122729T1 CY 20201100105 T CY20201100105 T CY 20201100105T CY 201100105 T CY201100105 T CY 201100105T CY 1122729 T1 CY1122729 T1 CY 1122729T1
- Authority
- CY
- Cyprus
- Prior art keywords
- vwf
- protein
- fragment
- fviii
- region
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title 1
- 108010047303 von Willebrand Factor Proteins 0.000 title 1
- 102100026735 Coagulation factor VIII Human genes 0.000 abstract 6
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 6
- 239000012634 fragment Substances 0.000 abstract 5
- 102000037865 fusion proteins Human genes 0.000 abstract 4
- 108020001507 fusion proteins Proteins 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 abstract 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Η παρούσα εφεύρεση περιλαμβάνει μια χιμαιρική πρωτεΐνη που αποτελείται από μια πρωτεΐνη VWF με D' περιοχή και D3 περιοχή του VWF, μια ή περισσότερες αλληλουχίες ΧΤΕΝ, και μια πρωτεΐνη FVIII, όπου το θραύσμα VWF, η αλληλουχία ΧΤΕΝ, ή η πρωτεΐνη FVIII συνδέονται σε ή σχετίζονται μεταξύ τους. Η χιμαιρική πρωτεΐνη μπορεί περαιτέρω να αποτελείται από μια ή περισσότερες σταθερές περιοχές Ιg ή ένα τμήμα αυτών (π.χ., μια Fc περιοχή). Μια πολυπεπτιδική αλυσίδα ενός θραύσματος VWF σχετίζεται με μια πολυπεπτιδική αλυσίδα FVIΙΙ συνδεδεμένη σε μια αλληλουχία ΧΤΕΝ. Το θραύσμα πολυπεπτιδικής αλυσίδας VWF μπορεί να αποτρέψει ή να αναστείλει την πρόσδεση ενδογενούς VWF σε πρωτεΐνη FVIΙΙ συνδεδεμένη στην αλληλουχία ΧΤΕΝ. Μέσω της αποτροπής ή αναστολής της πρόσδεσης ενδογενούς VWF σε πρωτεΐνη FVIII, το θραύσμα VWF μπορεί να επιμηκύνει την ημίσεια ζωή της χιμαιρικής πρωτεΐνης που αποτελείται από πρωτεΐνη FVIIΙ. Η εφεύρεση περιλαμβάνει νουκλεοτίδια, φορείς, κύτταρα ξενιστές, χρήση θραύσματος VWF, ή χιμαιρικές πρωτεΐνες.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261670401P | 2012-07-11 | 2012-07-11 | |
US201361759819P | 2013-02-01 | 2013-02-01 | |
US201361801504P | 2013-03-15 | 2013-03-15 | |
US201361801544P | 2013-03-15 | 2013-03-15 | |
US201361827158P | 2013-05-24 | 2013-05-24 | |
US201361840811P | 2013-06-28 | 2013-06-28 | |
PCT/US2013/049989 WO2014011819A2 (en) | 2012-07-11 | 2013-07-10 | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1122729T1 true CY1122729T1 (el) | 2021-03-12 |
Family
ID=49916682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100105T CY1122729T1 (el) | 2012-07-11 | 2020-02-05 | Συμπλοκο παραγοντα viii με χτεν και πρωτεϊνη παραγοντα von willebrand, και χρησεις αυτου |
Country Status (31)
Country | Link |
---|---|
US (3) | US10138291B2 (el) |
EP (3) | EP2882450B1 (el) |
JP (5) | JP6603128B2 (el) |
KR (2) | KR102329315B1 (el) |
CN (2) | CN104661674A (el) |
AR (1) | AR091735A1 (el) |
AU (4) | AU2013290173B2 (el) |
BR (1) | BR112015000267B1 (el) |
CA (1) | CA2878679A1 (el) |
CL (1) | CL2015000060A1 (el) |
CO (1) | CO7170123A2 (el) |
CY (1) | CY1122729T1 (el) |
DK (1) | DK2882450T3 (el) |
EA (2) | EA201792485A3 (el) |
ES (1) | ES2770501T3 (el) |
HK (1) | HK1211228A1 (el) |
HR (1) | HRP20200007T1 (el) |
HU (1) | HUE047088T2 (el) |
IL (1) | IL236412B (el) |
LT (1) | LT2882450T (el) |
MX (1) | MX2015000397A (el) |
NZ (1) | NZ703366A (el) |
PH (1) | PH12015500039A1 (el) |
PL (1) | PL2882450T3 (el) |
PT (1) | PT2882450T (el) |
RS (1) | RS59876B1 (el) |
SG (3) | SG11201500045RA (el) |
SI (1) | SI2882450T1 (el) |
TW (1) | TWI667258B (el) |
UA (1) | UA116632C2 (el) |
WO (1) | WO2014011819A2 (el) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ628987A (en) * | 2009-02-03 | 2015-11-27 | Amunix Operating Inc | Extended recombinant polypeptides and compositions comprising same |
US8716448B2 (en) | 2009-02-03 | 2014-05-06 | Amunix Operating Inc. | Coagulation factor VII compositions and methods of making and using same |
NZ626945A (en) | 2012-01-12 | 2016-10-28 | Biogen Ma Inc | Chimeric factor viii polypeptides and uses thereof |
KR20190094480A (ko) | 2012-02-15 | 2019-08-13 | 바이오버라티브 테라퓨틱스 인크. | 재조합 인자 viii 단백질 |
PT3564260T (pt) | 2012-02-15 | 2023-01-18 | Bioverativ Therapeutics Inc | Composições de fator viii e métodos de produção e utilização das mesmas |
EP2870250B2 (en) | 2012-07-06 | 2022-06-29 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor viii polypeptides and uses thereof |
SG11201500045RA (en) | 2012-07-11 | 2015-02-27 | Amunix Operating Inc | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
DK2956477T4 (da) | 2013-02-15 | 2024-04-15 | Bioverativ Therapeutics Inc | Optimeret faktor viii-gen |
TWI745671B (zh) | 2013-03-15 | 2021-11-11 | 美商百歐維拉提夫治療公司 | 因子ix多肽調配物 |
DK2796145T3 (da) * | 2013-04-22 | 2018-01-29 | Csl Ltd | Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro |
CN113831415A (zh) * | 2013-06-28 | 2021-12-24 | 比奥贝拉蒂治疗公司 | 具有xten的凝血酶可裂解连接子和其用途 |
TWI667255B (zh) | 2013-08-14 | 2019-08-01 | 美商生物化學醫療公司 | 因子viii-xten融合物及其用途 |
BR122023020301A2 (pt) * | 2014-01-10 | 2023-12-12 | Bioverativ Therapeutics Inc. | Uso de uma proteína quimérica compreendendo uma proteína fviii |
AU2016231328B2 (en) * | 2015-03-06 | 2018-07-05 | CSL Behring Lengnau AG | Compounds for improving the half-life of von Willebrand factor |
RU2017145014A (ru) * | 2015-05-22 | 2019-06-24 | Цсл Беринг Ленгнау Аг | Усеченные полипептиды фактора фон виллебранда для лечения гемофилии |
WO2017024060A1 (en) * | 2015-08-03 | 2017-02-09 | Biogen Ma Inc. | Factor ix fusion proteins and methods of making and using same |
AU2016304842A1 (en) | 2015-08-12 | 2018-02-22 | Cell Machines, Inc. | Methods and compositions related to long half-life coagulation complexes |
US11713358B2 (en) * | 2015-08-28 | 2023-08-01 | Amunix Pharmaceuticals, Inc. | Chimeric polypeptide assembly and methods of making and using the same |
WO2017117631A1 (en) | 2016-01-07 | 2017-07-13 | Csl Limited | Mutated truncated von willebrand factor |
US11753461B2 (en) | 2016-02-01 | 2023-09-12 | Bioverativ Therapeutics Inc. | Optimized factor VIII genes |
WO2017198435A1 (en) | 2016-05-20 | 2017-11-23 | Octapharma Ag | Glycosylated vwf fusion proteins with improved pharmacokinetics |
US11046749B2 (en) | 2016-06-24 | 2021-06-29 | Mogam Institute For Biomedical Research | Chimera protein comprising FVIII and vWF factors, and use thereof |
CN106279437B (zh) * | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
CN107759694B (zh) | 2016-08-19 | 2023-01-13 | 安源医药科技(上海)有限公司 | 双特异性抗体及其制备方法与用途 |
US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
CN110381986B (zh) | 2016-11-11 | 2023-08-18 | 康诺贝林伦瑙有限公司 | 用于血管外施予以治疗或预防凝血疾病的截短型冯维勒布兰德因子多肽 |
JP7252890B2 (ja) | 2016-11-11 | 2023-04-05 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 血友病を処置するための切断型フォン・ヴィルブランド因子ポリペプチド |
CN110520149A (zh) | 2016-12-02 | 2019-11-29 | 比奥维拉迪维治疗股份有限公司 | 诱导对凝血因子的免疫耐受性的方法 |
MX2019006444A (es) | 2016-12-02 | 2019-10-30 | Bioverativ Therapeutics Inc | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. |
CA3051862A1 (en) | 2017-01-31 | 2018-08-09 | Bioverativ Therapeutics Inc. | Factor ix fusion proteins and methods of making and using same |
GB201707139D0 (en) * | 2017-05-04 | 2017-06-21 | Imp Innovations Ltd | Polypeptides |
CA3072334A1 (en) | 2017-08-09 | 2019-02-14 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof |
US20200385469A1 (en) * | 2017-12-21 | 2020-12-10 | Amunix Pharmaceuticals, Inc. | Release segments and binding compositions comprising same |
BR112020022164A2 (pt) * | 2018-05-18 | 2021-02-02 | Bioverativ Therapeutics Inc. | métodos de tratamento de hemofilia a |
AU2019319984A1 (en) | 2018-08-09 | 2021-03-04 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
WO2020102741A1 (en) | 2018-11-15 | 2020-05-22 | Quantum-Si Incorporated | Methods and compositions for protein sequencing |
CA3121786A1 (en) | 2018-12-06 | 2020-06-11 | Bioverativ Therapeutics Inc. | Use of lentiviral vectors expressing factor ix |
US10654911B1 (en) * | 2019-04-02 | 2020-05-19 | Beijing Neoletix Biological Technology Co., Ltd. | Vector co-expressing truncated von Willebrand factor and factor VIII |
CA3144630A1 (en) * | 2019-06-19 | 2020-12-24 | Bioverativ Therapeutics Inc. | Methods and compositions for treating hemophilia and low bone mineral density |
CN112175088B (zh) * | 2019-07-02 | 2023-03-28 | 江苏晟斯生物制药有限公司 | 改进的fix融合蛋白、缀合物及其应用 |
WO2021043127A1 (zh) * | 2019-09-02 | 2021-03-11 | 甘李药业股份有限公司 | 嵌合蛋白 |
MX2022005676A (es) | 2019-11-13 | 2022-10-27 | Amunix Pharmaceuticals Inc | Polipéptidos xten con código de barras y composiciones de estos, y métodos para preparar y usar los mismos. |
EP4085077A4 (en) | 2019-12-31 | 2024-01-17 | Beijing Ql Biopharmaceutical Co Ltd | FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF |
CN113728013B (zh) | 2020-01-11 | 2022-06-14 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
KR20230012052A (ko) * | 2020-05-20 | 2023-01-25 | 퀀텀-에스아이 인코포레이티드 | 단백질 시퀀싱을 위한 방법 및 조성물 |
CN115925995A (zh) | 2020-09-30 | 2023-04-07 | 北京质肽生物医药科技有限公司 | 多肽缀合物和使用方法 |
EP4358938A1 (en) | 2021-06-23 | 2024-05-01 | Bioverativ Therapeutics Inc. | Formulations of factor viii chimeric proteins and uses thereof |
CN113862301A (zh) * | 2021-08-25 | 2021-12-31 | 上海交通大学医学院附属瑞金医院 | 一种vwf前肽表达载体及其制备方法和应用 |
Family Cites Families (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
WO1986006101A1 (en) | 1985-04-12 | 1986-10-23 | Genetics Institute, Inc. | Novel procoagulant proteins |
KR910006424B1 (ko) | 1985-08-21 | 1991-08-24 | 인코텍스 비.브이 | 편성브리프(brief) 제조방법 |
EP0253870B1 (en) | 1986-01-03 | 1993-03-31 | Genetics Institute, Inc. | Method for producing factor viii:c-type proteins |
US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US5610278A (en) | 1986-06-24 | 1997-03-11 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
IE69026B1 (en) | 1987-06-12 | 1996-08-07 | Immuno Ag | Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
FR2619314B1 (fr) | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
US4994371A (en) | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
US6037452A (en) | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
US6818439B1 (en) | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
CA2262405A1 (en) | 1996-08-02 | 1998-02-12 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
WO2000009560A2 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
US7829085B2 (en) | 1999-07-14 | 2010-11-09 | Life Sciences Research Partners Vzw | Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII |
WO2001079442A2 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
JP2003533537A (ja) | 2000-05-16 | 2003-11-11 | リポクセン テクノロジーズ リミテッド | タンパク質の誘導体化 |
GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
WO2002076489A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
KR101271635B1 (ko) | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
ES2500918T3 (es) | 2001-12-21 | 2014-10-01 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina e interferón beta |
US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20040018557A1 (en) | 2002-03-01 | 2004-01-29 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
AU2002316574B2 (en) | 2002-03-15 | 2008-05-01 | Brandeis University | Central airway administration for systemic delivery of therapeutics |
ATE536188T1 (de) | 2002-08-14 | 2011-12-15 | Macrogenics Inc | Fcgammariib-spezifische antikörper und verfahren zur verwendung davon |
WO2004027901A2 (en) | 2002-09-17 | 2004-04-01 | Diffusion Science, Inc. | Electrochemical generation, storage and reaction of hydrogen and oxygen using gas permeable catalyst-coated hollow microspheres |
ATE541857T1 (de) | 2002-09-27 | 2012-02-15 | Xencor Inc | Optimierte fc-varianten und herstellungsverfahren dafür |
JP4768439B2 (ja) | 2002-10-15 | 2011-09-07 | アボット バイオセラピューティクス コーポレイション | 変異誘発による抗体のFcRn結合親和力又は血清半減期の改変 |
GB2395337B (en) | 2002-11-14 | 2005-12-28 | Gary Michael Wilson | Warning Unit |
JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス,インコーポレーテッド | 変異型Fc領域を含む抗体の同定および作製ならびにその利用法 |
US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
KR101085375B1 (ko) | 2003-02-26 | 2011-11-21 | 넥타르 테라퓨틱스 | 중합체-인자 ⅷ 부분 콘쥬게이트 |
US7632895B2 (en) | 2003-02-28 | 2009-12-15 | Kuraray Co., Ltd. | Curable resin composition |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
DE602004031390D1 (de) | 2003-05-06 | 2011-03-24 | Syntonix Pharmaceuticals Inc | Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten |
JP4566194B2 (ja) | 2003-08-12 | 2010-10-20 | リポクセン テクノロジーズ リミテッド | タンパク質の誘導体化及び結合のためのシアル酸誘導体 |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
US20050249723A1 (en) | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
BRPI0506771A (pt) | 2004-01-12 | 2007-05-22 | Applied Molecular Evolution | anticorpo, e, composição farmacêutica |
AU2005227326B2 (en) | 2004-03-24 | 2009-12-03 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
EP3342782B1 (en) | 2004-07-15 | 2022-08-17 | Xencor, Inc. | Optimized fc variants |
US7566701B2 (en) | 2004-09-07 | 2009-07-28 | Archemix Corp. | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
WO2006071801A2 (en) * | 2004-12-27 | 2006-07-06 | Baxter International Inc | Polymer-von willebrand factor-conjugates |
WO2007021494A2 (en) | 2005-08-12 | 2007-02-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1996220B2 (en) | 2006-03-06 | 2023-08-16 | Amunix Operating Inc. | Unstructured recombinant polymers and uses thereof |
US7846445B2 (en) * | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
JP5800458B2 (ja) | 2006-06-14 | 2015-10-28 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 血液凝固因子を有するタンパク質分解によって切断可能な融合タンパク質 |
WO2008011633A2 (en) | 2006-07-21 | 2008-01-24 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
US20100254944A1 (en) | 2006-09-14 | 2010-10-07 | Mani Subramanian | Albumin Fusion Proteins |
US20100075375A1 (en) | 2006-10-03 | 2010-03-25 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
EP2068907B1 (en) | 2006-10-04 | 2017-11-29 | Novo Nordisk A/S | Glycerol linked pegylated sugars and glycopeptides |
JP5448839B2 (ja) * | 2006-12-22 | 2014-03-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | インビボで長い半減期を有する修飾された凝固因子 |
EP1935430A1 (en) | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
DK2173890T3 (da) | 2007-06-21 | 2011-06-27 | Univ Muenchen Tech | Biologisk aktive proteiner med forhøjet stabilitet in vivo og/eller in vitro |
EP2185701A4 (en) | 2007-08-15 | 2011-03-02 | Amunix Operating Inc | COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES |
WO2009058446A1 (en) | 2007-11-01 | 2009-05-07 | University Of Rochester | Recombinant factor viii having increased stability |
KR20100095441A (ko) | 2007-11-09 | 2010-08-30 | 백스터 인터내셔널 인코포레이티드 | 변형된 재조합 인자 ⅷ 및 폰 빌레브란트 인자 및 사용 방법 |
CN101952016A (zh) | 2007-12-28 | 2011-01-19 | 巴克斯特国际公司 | 重组vwf配方 |
ES2531464T3 (es) * | 2008-06-24 | 2015-03-16 | Csl Behring Gmbh | Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada |
CA2744340A1 (en) | 2008-11-24 | 2010-05-27 | Bayer Healthcare Llc | Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay |
US8716448B2 (en) | 2009-02-03 | 2014-05-06 | Amunix Operating Inc. | Coagulation factor VII compositions and methods of making and using same |
NZ628987A (en) | 2009-02-03 | 2015-11-27 | Amunix Operating Inc | Extended recombinant polypeptides and compositions comprising same |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
EP3061460A1 (en) | 2009-04-10 | 2016-08-31 | Tufts Medical Center, Inc. | Par-1 activation by metalloproteinase-1 (mmp-1) |
CN102481331B (zh) | 2009-06-08 | 2017-09-22 | 阿穆尼克斯运营公司 | 葡萄糖调节多肽及其制备和使用方法 |
NZ621868A (en) | 2009-06-08 | 2015-10-30 | Amunix Operating Inc | Growth hormone polypeptides and methods of making and using same |
KR20120061898A (ko) | 2009-08-20 | 2012-06-13 | 체에스엘 베링 게엠베하 | 출혈성 장애의 치료요법 및 예방 치료에 있어서의 비정맥내 투여를 위한 알부민 융합 응고 인자 |
WO2011028344A2 (en) | 2009-08-25 | 2011-03-10 | Amunix Operating Inc. | Interleukin-1 receptor antagonist compositions and methods of making and using same |
AU2010319425B2 (en) * | 2009-11-13 | 2015-07-02 | Grifols Therapeutics Inc. | Von Willebrand factor (vWF)-containing preparations, and methods, kits, and uses related thereto |
US9050318B2 (en) * | 2009-12-06 | 2015-06-09 | Biogen Idec Hemophilia Inc. | Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof |
EP2536753B1 (en) * | 2010-02-16 | 2017-12-20 | Novo Nordisk A/S | Factor viii molecules with reduced vwf binding |
EP2977055A1 (en) | 2010-02-16 | 2016-01-27 | Novo Nordisk A/S | Factor viii fusion protein |
CA2799969C (en) | 2010-05-20 | 2019-06-25 | Allergan, Inc. | Degradable clostridial toxins |
AU2011274423B2 (en) | 2010-07-09 | 2016-02-11 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
WO2012006623A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Systems for factor viii processing and methods thereof |
US20130017997A1 (en) | 2010-08-19 | 2013-01-17 | Amunix Operating Inc. | Factor VIII Compositions and Methods of Making and Using Same |
NZ626945A (en) * | 2012-01-12 | 2016-10-28 | Biogen Ma Inc | Chimeric factor viii polypeptides and uses thereof |
PT3564260T (pt) | 2012-02-15 | 2023-01-18 | Bioverativ Therapeutics Inc | Composições de fator viii e métodos de produção e utilização das mesmas |
KR20190094480A (ko) | 2012-02-15 | 2019-08-13 | 바이오버라티브 테라퓨틱스 인크. | 재조합 인자 viii 단백질 |
SG11201500045RA (en) | 2012-07-11 | 2015-02-27 | Amunix Operating Inc | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
CN113831415A (zh) | 2013-06-28 | 2021-12-24 | 比奥贝拉蒂治疗公司 | 具有xten的凝血酶可裂解连接子和其用途 |
WO2014210547A1 (en) | 2013-06-28 | 2014-12-31 | Biogen Idec Ma Inc. | Thrombin cleavable linker |
BR122023020301A2 (pt) | 2014-01-10 | 2023-12-12 | Bioverativ Therapeutics Inc. | Uso de uma proteína quimérica compreendendo uma proteína fviii |
BR112020022164A2 (pt) * | 2018-05-18 | 2021-02-02 | Bioverativ Therapeutics Inc. | métodos de tratamento de hemofilia a |
-
2013
- 2013-07-10 SG SG11201500045RA patent/SG11201500045RA/en unknown
- 2013-07-10 MX MX2015000397A patent/MX2015000397A/es unknown
- 2013-07-10 EP EP13816031.2A patent/EP2882450B1/en active Active
- 2013-07-10 PL PL13816031T patent/PL2882450T3/pl unknown
- 2013-07-10 HU HUE13816031A patent/HUE047088T2/hu unknown
- 2013-07-10 NZ NZ703366A patent/NZ703366A/en unknown
- 2013-07-10 CN CN201380046914.5A patent/CN104661674A/zh active Pending
- 2013-07-10 ES ES13816031T patent/ES2770501T3/es active Active
- 2013-07-10 EA EA201792485A patent/EA201792485A3/ru unknown
- 2013-07-10 WO PCT/US2013/049989 patent/WO2014011819A2/en active Application Filing
- 2013-07-10 DK DK13816031.2T patent/DK2882450T3/da active
- 2013-07-10 CN CN201811639711.8A patent/CN110054699A/zh active Pending
- 2013-07-10 PT PT138160312T patent/PT2882450T/pt unknown
- 2013-07-10 SG SG10201701037WA patent/SG10201701037WA/en unknown
- 2013-07-10 AU AU2013290173A patent/AU2013290173B2/en active Active
- 2013-07-10 SI SI201331656T patent/SI2882450T1/sl unknown
- 2013-07-10 CA CA2878679A patent/CA2878679A1/en active Pending
- 2013-07-10 JP JP2015521785A patent/JP6603128B2/ja active Active
- 2013-07-10 RS RS20200123A patent/RS59876B1/sr unknown
- 2013-07-10 SG SG10201913893XA patent/SG10201913893XA/en unknown
- 2013-07-10 KR KR1020157003523A patent/KR102329315B1/ko active IP Right Grant
- 2013-07-10 KR KR1020217037450A patent/KR102403545B1/ko active IP Right Grant
- 2013-07-10 BR BR112015000267-6A patent/BR112015000267B1/pt active IP Right Grant
- 2013-07-10 EP EP19210390.1A patent/EP3674410A1/en not_active Withdrawn
- 2013-07-10 LT LTEP13816031.2T patent/LT2882450T/lt unknown
- 2013-07-10 EP EP23179872.9A patent/EP4269431A1/en active Pending
- 2013-07-10 US US14/413,765 patent/US10138291B2/en active Active
- 2013-07-10 EA EA201590198A patent/EA029685B1/ru unknown
- 2013-07-11 TW TW102124926A patent/TWI667258B/zh active
- 2013-07-11 AR ARP130102467A patent/AR091735A1/es not_active Application Discontinuation
- 2013-10-07 UA UAA201500228A patent/UA116632C2/uk unknown
-
2014
- 2014-12-23 IL IL236412A patent/IL236412B/en active IP Right Grant
-
2015
- 2015-01-07 PH PH12015500039A patent/PH12015500039A1/en unknown
- 2015-01-09 CL CL2015000060A patent/CL2015000060A1/es unknown
- 2015-01-16 CO CO15008422A patent/CO7170123A2/es unknown
- 2015-12-08 HK HK15112122.9A patent/HK1211228A1/xx unknown
-
2018
- 2018-04-06 JP JP2018073823A patent/JP2018102323A/ja not_active Withdrawn
- 2018-05-08 AU AU2018203206A patent/AU2018203206B2/en active Active
- 2018-10-08 US US16/154,310 patent/US11091534B2/en active Active
-
2020
- 2020-01-03 HR HRP20200007TT patent/HRP20200007T1/hr unknown
- 2020-02-05 CY CY20201100105T patent/CY1122729T1/el unknown
- 2020-03-04 JP JP2020036624A patent/JP7022165B2/ja active Active
- 2020-11-05 AU AU2020264355A patent/AU2020264355A1/en not_active Abandoned
-
2021
- 2021-06-25 US US17/358,142 patent/US20220056108A1/en active Pending
- 2021-10-04 JP JP2021163423A patent/JP2022000471A/ja not_active Withdrawn
-
2022
- 2022-10-10 AU AU2022252703A patent/AU2022252703A1/en active Pending
-
2023
- 2023-10-02 JP JP2023171467A patent/JP2023166024A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122729T1 (el) | Συμπλοκο παραγοντα viii με χτεν και πρωτεϊνη παραγοντα von willebrand, και χρησεις αυτου | |
CY1122509T1 (el) | Πολυπεπτιδια χιμαιρικου παραγοντα viii και χρησεις αυτων | |
CY1121962T1 (el) | Υποδοχεις τ κυτταρου | |
EA201691111A1 (ru) | Химерные белки фактора viii и их применение | |
CY1123220T1 (el) | Πρωτεϊνες συνδεσης anti-lag-3 | |
CY1122691T1 (el) | Πρωτεϊνες δεσμευσης αλβουμινης ορου | |
CY1124664T1 (el) | Υποδοχεις τ λεμφοκυτταρων | |
CY1122435T1 (el) | Ποντικοι με εξανθρωπισμενη καθολικη ελαφρια αλυσιδα | |
CY1114626T1 (el) | Μεθοδοι κυκλοπολυαιθυλενογλυκολιωσης και πρωτεϊνες/πεπτιδια που παραγονται με αυτες τις μεθοδους | |
EA201592022A1 (ru) | Расщепляемый тромбином линкер, содержащий xten, и его применение | |
CY1119647T1 (el) | Αντισωματα προσδεσης αλβουμινης και τμηματα προσδεσης αυτων | |
ES2676023T3 (es) | Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso | |
PE20091004A1 (es) | Proteinas de union a antigenos c-fms humanos | |
ES2691539T3 (es) | Luciferasas de Oplophorus sintéticas con mayor emisión de luz | |
EA201892217A1 (ru) | Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, КОТОРЫЕ РАСПОЗНАЮТ МУТАНТНЫЕ ВАРИАНТЫ СО СДВИГОМ РАМКИ СЧИТЫВАНИЯ TGFβRII | |
UA108778C2 (xx) | Протираковий злитий протеїн | |
CL2009001284A1 (es) | Anticuerpos o fragmentos de union a antigeno del mismo que se unen a il-21r; composicion farmaceutica que lo comprende; acidos nucleicos codificantes; vectores de expresion y celulas huesped aisladas; kit de diagnostico que comprende a dichos anticuerpos | |
ATE466874T1 (de) | Mit scytovirin der domäne 1 verwandte polypeptide | |
CY1119164T1 (el) | Πεπτιδια που προερχονται απο τον παραγοντα viii για χρηση στη θεραπεια της αιμορροφιλιας α | |
TH1501000097A (th) | สารเชิงซ้อนของแฟคเตอร์ viii ประกอบกับ xten และโปรตีนของวอน วิลลีแบรนด์ แฟคเตอร์ และการใช้งาน | |
TH175654A (th) | พอลิเปปไทด์แฟกเตอร์ไคเมอริก viii และการใช้ของสิ่งเหล่านั้น | |
BR112021017464A2 (pt) | Receptores de células t e métodos de uso dos mesmos | |
UA108911C2 (xx) | Протираковий злитий протеїн | |
TH1501006811A (th) | ตัวเชื่อมที่มี xten ที่แยกออกได้ด้วยทรอมบิน และการใช้ตัวเชื่อมดังกล่าว |